Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic avenue for managing metabolic syndromes. These naturally occurring hormones are secreted by approved peptide manufacturer. the gut in response to food intake, stimulating insulin production and suppressing glucagon output. GLP-1 agents exhibit promising therapeutic ef